MRNA - Moderna Inc Stock Price, Fair Value and News

121.06USD-1.63 (-1.33%)Delayed as of 10 May 2024, 10:24 am ET

Market Summary

USD121.06-1.63

Delayedas of 10 May 2024, 10:24 am

-1.33%

MRNA Alerts

2 major insider sales recently.

Big fall in earnings (Y/Y)
Losses in recent quarter

MRNA Stock Price

View Fullscreen

MRNA RSI Chart

MRNA Valuation

Market Cap

47.0B

Price/Earnings (Trailing)

-7.88

Price/Sales (Trailing)

6.87

EV/EBITDA

-10.08

Price/Free Cashflow

-12.8

MRNA Price/Sales (Trailing)

MRNA Profitability

EBT Margin

-70.12%

Return on Equity

-46.56%

Return on Assets

-35.67%

Free Cashflow Yield

-7.81%

MRNA Fundamentals

MRNA Revenue

Revenue (TTM)

6.8B

Rev. Growth (Yr)

-44.71%

Rev. Growth (Qtr)

53.52%

MRNA Earnings

Earnings (TTM)

-6.0B

Earnings Growth (Yr)

-1.6K%

Earnings Growth (Qtr)

-641.47%

Breaking Down MRNA Revenue

52 Week Range

95.02142.79

(Low)(High)

Last 7 days

-2.3%

Last 30 days

9.9%

Last 90 days

40.4%

Trailing 12 Months

-6.2%

How does MRNA drawdown profile look like?

MRNA Financial Health

Current Ratio

4.03

MRNA Investor Care

Shares Dilution (1Y)

0.53%

Diluted EPS (TTM)

-15.63

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	0	0	0	0
2023	15.1B	10.7B	9.1B	6.8B
2022	22.6B	23.0B	21.4B	19.3B
2021	2.7B	7.0B	11.8B	18.5B
2020	52.2M	106.1M	246.1M	803.0M
2019	122.1M	106.3M	81.6M	60.2M
2018	204.5M	192.3M	191.6M	135.1M
2017	132.8M	157.1M	181.5M	205.8M
2016	0	0	0	108.4M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Moderna Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
May 03, 2024	nabel elizabeth g	acquired	-	-	732	-
May 03, 2024	berenson stephen	acquired	-	-	732	-
May 01, 2024	afeyan noubar	sold	-1,663,850	110	-15,000	-
Apr 24, 2024	afeyan noubar	sold	-1,624,840	108	-15,000	-
Apr 17, 2024	afeyan noubar	sold	-1,550,700	103	-15,000	-
Apr 15, 2024	hoge stephen	sold	-1,575,300	105	-15,000	president
Apr 10, 2024	afeyan noubar	sold	-1,606,860	107	-15,000	-
Apr 08, 2024	mock james m	sold	-71,859	101	-705	chief financial officer
Apr 05, 2024	mock james m	acquired	-	-	1,453	chief financial officer
Apr 03, 2024	afeyan noubar	sold	-1,525,270	101	-15,000	-

Which funds bought or sold MRNA recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
May 08, 2024	STEVENS CAPITAL MANAGEMENT LP	sold off	-100	-739,000	-	-%
May 08, 2024	Russell Investments Group, Ltd.	reduced	-2.69	423,930	7,071,960	0.01%
May 08, 2024	Eagle Bay Advisors LLC	unchanged	-	234	3,516	-%
May 08, 2024	Jackson, Grant Investment Advisers, Inc.	unchanged	-	56.00	852	-%
May 08, 2024	Value Star Asset Management (Hong Kong) Ltd	unchanged	-	222,000	3,329,000	1.15%
May 08, 2024	Achmea Investment Management B.V.	sold off	-100	-2,761,000	-	-%
May 08, 2024	EMERALD ADVISERS, LLC	reduced	-37.69	-169,783	340,992	0.01%
May 08, 2024	Belpointe Asset Management LLC	added	16.95	384,205	1,902,310	0.14%
May 08, 2024	Bell Investment Advisors, Inc	added	7.14	1,030	7,992	-%
May 08, 2024	COMMONWEALTH OF PENNSYLVANIA PUBLIC SCHOOL EMPLS RETRMT SYS	added	0.25	535,665	7,759,910	0.05%

Are Funds Buying or Selling MRNA?

Are funds buying MRNA calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own MRNA

No. of Funds

Unveiling Moderna Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Apr 10, 2024	vanguard group inc	10.20%	39,036,765	SC 13G/A
Feb 13, 2024	vanguard group inc	8.89%	33,906,974	SC 13G/A
Feb 07, 2024	bancel stephane	7.8%	30,384,866	SC 13G/A
Jan 29, 2024	blackrock inc.	6.6%	25,301,057	SC 13G/A
Jan 29, 2024	baillie gifford & co	11.97%	45,654,527	SC 13G/A
Feb 10, 2023	bancel stephane	7.41%	29,151,802	SC 13G/A
Feb 09, 2023	vanguard group inc	7.10%	27,282,173	SC 13G/A
Feb 01, 2023	blackrock inc.	6.8%	26,115,224	SC 13G/A
Jan 19, 2023	baillie gifford & co	11.66%	44,786,746	SC 13G/A
Feb 14, 2022	bancel stephane	7.64%	31,538,184	SC 13G/A

Recent SEC filings of Moderna Inc

View All Filings

Date Filed	Form Type	Document
May 09, 2024	8-K	Current Report
May 08, 2024	144	Notice of Insider Sale Intent
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading
May 07, 2024	4	Insider Trading

Peers (Alternatives to Moderna Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
MRNA	47.0B	6.8B	9.93%	-6.23%	-7.88	6.87	-64.45%	-224.75%
HILS	22.5B	216.3K	-0.77%	465779.94%	-2.5K	104.0K	-	-8.13%
ALNY	19.2B	2.0B	-2.86%	-28.22%	-57.69	9.56	75.20%	68.82%
BMRN	15.5B	2.5B	-8.14%	-14.08%	75.54	6.28	13.74%	186.89%
INCY	12.0B	3.8B	-3.24%	-16.29%	16.12	3.19	8.58%	129.81%
MID-CAP
BBIO	5.4B	107.9M	1.09%	107.81%	-9.83	48.09	54.84%	-28.31%
APLS	5.2B	524.1M	-22.77%	-53.41%	-12.37	9.85	394.93%	39.61%
AXSM	3.5B	251.0M	1.40%	-8.18%	-11.81	13.94	73.58%	-86.73%
ARWR	3.1B	240.7M	-5.68%	-38.85%	-6.52	12.77	-1.03%	-213.43%
ACAD	2.5B	813.8M	-16.31%	-29.84%	-1.5K	3.09	56.43%	98.83%
SMALL-CAP
CPRX	1.9B	411.3M	-0.76%	-10.51%	28.42	4.5	60.38%	-34.49%
NVAX	627.0M	983.7M	1.36%	-50.17%	-1.15	0.64	-50.36%	17.16%
CRBP	467.5M	881.7K	16.76%	369.92%	-13.85	481.06	-77.61%	33.36%
INO	260.8M	4.9M	-4.04%	14.81%	-1.93	53.59	-54.97%	51.71%
IBIO	6.4M	2.1M	-14.75%	74.53%	-0.24	2.14	-13.45%	66.37%

Moderna Inc News

Latest updates

Moderna Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Income Statement (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Revenue	-100.0%	-	2,811	1,831	344	1,862	5,084	3,364	4,749	6,066	7,211	4,969	4,354	1,937	571	157	67.00	8.00	14.00	17.00	13.00	16.00
Costs and Expenses	-48.9%	1,433	2,805	3,843	2,211	2,228	3,504	2,198	2,302	1,839	1,801	1,411	1,292	671	846	392	189	139	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	393	188	139	145	148	157	158
S&GA Expenses	-100.0%	-	470	442	332	305	375	278	211	268	201	168	121	77.00	79.00	48.00	37.00	24.00	26.00	28.00	28.00	27.00
R&D Expenses	-24.4%	1,063	1,406	1,160	1,148	1,131	1,211	820	710	554	648	521	421	401	759	344	152	115	118	120	128	130
EBITDA Margin	-Infinity%	-0.65*	-	-0.22*	0.11*	0.36*	0.52*	0.64*	0.70*	0.73*	0.73*	0.66*	0.56*	0.25*	-	-	-	-	-	-	-	-
Income Taxes	106.8%	10.00	-147	1,672	-369	-384	190	174	277	572	542	219	283	39.00	2.00	1.00	-	-	-0.47	-0.18	-0.32	-0.02
Earnings Before Taxes	-1764.3%	-1,165	70.00	-1,958	-1,749	-305	1,655	1,217	2,474	4,229	5,410	3,552	3,063	1,260	-271	-232	-117	-124	-123	-123	-135	-132
EBT Margin	-21.8%	-0.70*	-0.58*	-0.26*	0.08*	0.33*	0.50*	0.62*	0.68*	0.72*	0.72*	0.64*	0.54*	-	-	-	-	-	-	-	-	-
Net Income	-641.5%	-1,175	217	-3,630	-1,380	79.00	1,465	1,043	2,197	3,657	4,868	3,333	2,780	1,221	-273	-233	-117	-124	-123	-123	-134	-132
Net Income Margin	-26.6%	-0.87*	-0.69*	-0.38*	0.11*	0.32*	0.43*	0.55*	0.61*	0.65*	0.66*	0.60*	0.50*	-	-	-	-	-	-	-	-	-
Free Cashflow	-394.8%	-1,185	402	-1,740	-1,149	-1,338	1,570	163	217	2,631	3,190	3,177	4,033	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Assets	-9.2%	16,729	18,426	19,450	21,884	24,125	25,858	26,056	26,043	27,609	24,669	20,923	16,153	12,694	7,337	4,651	3,486	2,068	1,589	1,591	1,685	1,806
Current Assets	-7.0%	9,600	10,325	10,799	10,599	12,122	13,431	14,297	13,563	16,350	16,071	13,425	10,969	11,703	6,298	3,577	2,797	1,250	1,129	1,094	1,097	1,141
Cash Equivalents	-28.8%	2,071	2,907	2,932	3,801	3,441	3,205	3,027	2,873	5,048	6,848	5,550	5,603	5,442	2,636	1,506	1,762	392	248	174	152	503
Inventory	46.0%	295	202	487	715	732	949	2,077	1,921	1,942	1,441	965	643	494	47.00	-	-	-	-	-	-	-
Net PPE	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	204	209	213
Liabilities	-14.4%	3,912	4,572	5,995	4,935	5,262	6,735	8,064	8,058	10,534	10,524	10,799	9,449	8,856	4,776	1,891	539	427	415	339	347	360
Current Liabilities	-21.1%	2,380	3,015	4,385	3,123	3,499	4,923	6,807	6,812	9,238	9,128	9,957	8,840	8,441	4,389	1,474	162	135	143	148	162	159
Shareholder's Equity	-7.5%	12,817	13,854	13,455	16,949	18,863	19,123	17,992	17,985	17,075	14,145	10,124	6,704	3,838	2,561	2,760	2,947	1,641	1,175	1,248	1,335	1,442
Retained Earnings	-8.6%	12,431	13,606	13,389	17,019	18,399	18,320	16,855	15,812	13,615	9,958	5,090	1,757	-1,023	-2,244	-1,970	-1,737	-1,620	-1,496	-1,369	-1,246	-1,111
Additional Paid-In Capital	31.3%	487	371	277	193	731	1,173	1,488	2,413	3,644	4,211	5,003	4,931	4,860	4,802	4,726	4,676	3,268	2,669	2,618	2,582	2,557
Shares Outstanding	0.3%	383	382	381	381	384	385	396	399	402	403	402	401	-	-	-	-	-	-	-	-	-
Float	-	-	-	-	40,200	-	-	-	48,800	-	-	-	80,800	-	-	-	25,250	-	-	-	3,380	-

Cashflow (Last 12 Months)

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Cashflow (Quarterly)																					(In Millions)
Description	(%) Q/Q	2024Q1	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1
Cashflow From Operations	-259.0%	-989	622	-1,600	-915	-1,225	1,662	252	304	2,763	3,310	3,276	4,063	2,971	1,264	893	-24.00	-106	-99.05	-107	-108	-144
Share Based Compensation	27.8%	101	79.00	77.00	74.00	75.00	62.00	70.00	50.00	44.00	37.00	40.00	35.00	30.00	26.00	22.00	25.00	20.00	20.00	21.00	21.00	18.00
Cashflow From Investing	121.9%	118	-538	789	1,944	2,011	-1,048	945	-1,152	-3,921	-1,138	-3,327	-3,878	-180	-190	-1,179	13.00	-316	130	113	-246	-11.76
Cashflow From Financing	112.8%	14.00	-109	-58.00	-668	-542	-438	-1,041	-1,327	-642	-873	-2.00	-24.00	26.00	44.00	30.00	1,381	578	32.00	16.00	4.00	0.00
Buy Backs	-	-	-	-1.00	628	526	402	1,006	1,298	623	857	-	-	-	-	-	-	-	-	-	-	-

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

MRNA Income Statement

2024-03-31

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) shares in Millions, $ in Millions	3 Months Ended
	Mar. 31, 2024	Mar. 31, 2023
Revenue:
Total revenue	$ 167	$ 1,862
Operating expenses:
Cost of sales	96	792
Research and development	1,063	1,131
Selling, general and administrative	274	305
Total operating expenses	1,433	2,228
Loss from operations	(1,266)	(366)
Interest income	120	109
Other expense, net	(19)	(48)
Loss before income taxes	(1,165)	(305)
Provision for (benefit from) income taxes	10	(384)
Net (loss) income	$ (1,175)	$ 79
(Loss) earnings per share:
Basic (in usd per share)	$ (3.07)	$ 0.20
Diluted (in usd per share)	$ (3.07)	$ 0.19
Weighted average common shares used in calculation of (loss) earnings per share:
Basic (in shares)	382	386
Diluted (in shares)	382	405
Net product sales
Revenue:
Total revenue	$ 167	$ 1,828
Other revenue
Revenue:
Total revenue	$ 0	$ 34

MRNA Balance Sheet

2024-03-31

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Millions	Mar. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 2,051	$ 2,907
Investments	6,472	5,697
Accounts receivable, net	137	892
Inventory	295	202
Prepaid expenses and other current assets	645	627
Total current assets	9,600	10,325
Investments, non-current	3,638	4,677
Property, plant and equipment, net	2,063	1,945
Right-of-use assets, operating leases	697	713
Deferred tax assets	81	81
Other non-current assets	650	685
Total assets	16,729	18,426
Current liabilities:
Accounts payable	183	520
Accrued liabilities	1,396	1,798
Deferred revenue	559	568
Income taxes payable	52	63
Other current liabilities	190	66
Total current liabilities	2,380	3,015
Deferred revenue, non-current	58	83
Operating lease liabilities, non-current	637	643
Financing lease liabilities, non-current	575	575
Other non-current liabilities	262	256
Total liabilities	3,912	4,572
Commitments and contingencies (Note 11)
Stockholders’ equity:
Preferred stock, par value $0.0001; 162 shares authorized as of March 31, 2024 and December 31, 2023; no shares issued or outstanding at March 31, 2024 and December 31, 2023	0	0
Common stock, par value $0.0001; 1,600 shares authorized as of March 31, 2024 and December 31, 2023; 383 and 382 shares issued and outstanding as of March 31, 2024 and December 31, 2023, respectively	0	0
Additional paid-in capital	487	371
Accumulated other comprehensive loss	(101)	(123)
Retained earnings	12,431	13,606
Total stockholders’ equity	12,817	13,854
Total liabilities and stockholders’ equity	$ 16,729	$ 18,426

About Moderna Inc

Moderna, Inc., a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, flu, respiratory syncytial virus, Endemic HCoV, and hMPV+PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella-zoster virus, and human immunodeficiency virus vaccines; and public health vaccines consists of Zika and Nipah vaccines. The company also offers systemic secreted and cell surface therapeutics; cancer vaccines, such as personalized cancer, KRAS, and checkpoint vaccines; intratumoral immuno-oncology products; localized regenerative, systemic intracellular, and inhaled pulmonary therapeutics. It has strategic alliances and collaborations with AstraZeneca; Merck; Vertex Pharmaceuticals Incorporated; Vertex Pharmaceuticals (Europe) Limited; Chiesi Farmaceutici S.p.A.; Metagenomi, Inc.; Carisma Therapeutics, Inc.; CytomX Therapeutics; Defense Advanced Research Projects Agency; Biomedical Advanced Research and Development Authority; Institute for Life Changing Medicines; and The Bill & Melinda Gates Foundation, as well as a collaboration agreement with CARsgen Therapeutics Holdings Limited to evaluate CTO41in combination with mRNA cancer vaccine. The company was formerly known as Moderna Therapeutics, Inc. and changed its name to Moderna, Inc. in August 2018. Moderna, Inc. was founded in 2010 and is headquartered in Cambridge, Massachusetts.

CEO	Mr. Stephane Bancel
WEBSITE	modernatx.com
INDUSTRY	Biotechnology
EMPLOYEES	3900

Moderna Inc Frequently Asked Questions

What is the ticker symbol for Moderna Inc? What does MRNA stand for in stocks?

MRNA is the stock ticker symbol of Moderna Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Moderna Inc (MRNA)?

As of Thu May 09 2024, market cap of Moderna Inc is 47.02 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of MRNA stock?

You can check MRNA's fair value in chart for subscribers.

What is the fair value of MRNA stock?

You can check MRNA's fair value in chart for subscribers. The fair value of Moderna Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Moderna Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for MRNA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Moderna Inc a good stock to buy?

The fair value guage provides a quick view whether MRNA is over valued or under valued. Whether Moderna Inc is cheap or expensive depends on the assumptions which impact Moderna Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for MRNA.

What is Moderna Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu May 09 2024, MRNA's PE ratio (Price to Earnings) is -7.88 and Price to Sales (PS) ratio is 6.87. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. MRNA PE ratio will change depending on the future growth rate expectations of investors.